Syndax(US:SNDX)2026-02-26 22:32Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [33] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [33] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [18][33] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [6][7] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax [8][9] Market Data and Key Metrics Changes - The KMT2A business showed continued growth as the number of patients on therapy post-transplant began to increase significantly [7] - The NPM1 market opportunity is estimated to triple the annual addressable patient population to 6,500 patients, with early data indicating strong uptake [13][15] Company Strategy and Development Direction - Syndax aims to expand its market share in menin inhibition, with Revuforj positioned as the leading menin inhibitor in both relapsed refractory and frontline settings [36] - The company is focused on advancing its pipeline, including pivotal trials for revumenib and axatilimab, to unlock significant market opportunities [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Revuforj and Niktimvo, supported by strong customer relationships and clinical data [9][11] - The company is well-funded with $394 million in cash and equivalents, expecting to reach profitability without additional capital [35] Other Important Information - Syndax completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [10][28] - The company anticipates stable expenses in 2026, guiding total R&D plus SG&A expenses to approximately $400 million [35] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A has been significant, with a third of patients going to transplant and an increasing number returning for maintenance therapy, which is expected to continue growing [40][41] Question: What is the expected steady state for NPM1 patient starts? - Management indicated that they expect the percentage of NPM1 patient starts to grow significantly, potentially reaching a 50/50 split with KMT2A patients as awareness and access improve [43][45] Question: What are the criteria for determining the go-forward decision on the IPF indication? - Management highlighted the importance of statistical significance and clinical relevance against historical controls, with a focus on achieving a meaningful difference in forced vital capacity [47][49] Question: How quickly can a pivotal trial for IPF be initiated if the phase II trial reads out positively? - Management expressed intent to design and execute the next trial as quickly as possible, with plans for a phase III trial based on the positive results from the phase II study [52][53] Question: Are physicians comfortable with the dosing of Revuforj in maintenance therapy? - Management confirmed that physicians are becoming more comfortable with the dosing as maintenance use increases, supported by ongoing studies to optimize dosing [61][62] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - Management explained that they are pursuing innovative approaches, including trials with venetoclax, to potentially reduce morbidity while achieving similar outcomes to intensive chemotherapy [66][67]